无机汞对男工内分泌和大鼠睾丸微量元素的影响

应用放射免疫分析法（ＲＩＡ）和流行病学调查，对４０名接触汞和４０名非接触汞男工进行了血清甲状腺激素、性激素水平和生殖功能的测定。结果表明，接触组男工的阳萎、早泄、性欲减退发生率和男工妻子的早产、自然流产发生率以及血清甲状腺激素（ＦＴ３和ＦＴ４）含量明显增多，每周性交次数和血清睾酮含量显著减少。上述各项与对照组比较差异非常显著。应用火焰光度法，对氯化汞染毒后大鼠睾丸组织的微量元素进行测定，实验组的锌值明显降低。结果提示氯化汞能够影响甲状腺激素、睾酮和锌元素水平。     

7-氯苄基四氢巴马汀对大鼠心肌肥厚及左心室肌原纤维Ca~(2 )-Mg~(2 )-ATP酶活力的影响

目的观察 7-氯苄基四氢巴马汀 ( 7-chlor -BTHP)对大鼠心肌肥厚和心室肌原纤维质膜Ca2 -Mg2 -ATP酶活力的影响。方法用L -甲状腺素诱发大鼠心肌肥厚 ,然后观察 7-chlor -BTHP对大鼠心肌肥厚及左心室肌原纤维Ca2 -Mg2 -ATPase的影响 ,以普萘洛尔 (Pro)作为阳性对照。结果经过 7-chlor-BTHP治疗 3天后 ,心肌肥厚明显改善 ,Ca2 -Mg2 -ATPase活力明显降低。结论 7-chlor-BTHP能明显消退L -甲状腺素诱发的大鼠心肌肥厚 ,并能显著降低心室肌原纤维膜Ca2 -Mg2 -ATPase酶活力。     

甲状腺素在抗甲状腺药物治疗格雷夫斯病复发中的作用

目的：探讨格雷夫斯病（Graves,diseaes)经抗甲状腺药物（ATD）治疗后用甲状腺素减少复发的效果。方法：对新确立诊断的60例Graves病患者,在他巴唑治疗0．5年后,随机分为3组：A组：给予小剂量他巴唑加左旋甲状腺素（L－T4）50μg/d;B组：单纯小剂量他巴唑治疗;C组：同A组。治疗24个月后,A组停他巴唑,单用L－T4 50μg/d;B组继续以他巴唑维持量,C组他巴唑维持量加L－T4 50μg/d,半年后停药随访。结果A、C组TSAb;B组继续以他巴唑维持量,C组他巴唑维持量加L－T450μg/d,半年后停药随访。结果A、C组TSAb滴度较B组低,但3组停药1年内复发率差异无显著意义,分别为4／20,20％、5．20,25％和4／20,20％,结论他巴唑加用甲状腺素以及延长甲腺素的治疗,较单用巴唑治疗Graves病并不能更好地降低复发率,促甲状腺素受体抗体水平尚不足Graves病复发的惟一因素。     

Differences in Bone Turnover and Skeletal Response to Thyroid Hormone Treatment Between Estrogen-Depleted and Repleted Rats

This study was undertaken to compare the effect of supraphysiological doses of thyroxine (T4) on bone metabolism in SHAM and OVX young adult rats. Female Sprague Dawley rats (220 ± 2 g, approx. 5 months of age) were divided into four groups of eight animals each. The animals were intraperitoneally injected 6 days per week with vehicle (Vh): 0.001 N NaOH/0.9% NaCl (SHAM+Vh and OVX+Vh) or 250 μg of thyroxine/kg/day (SHAM+T4 and OVX+T4) during a 5-week period. Serum T4 and osteocalcin (BGP), urinary pyridinolines (Pyr), and creatinine (creat) were determined. At the beginning and at end of the experiment, skeletal bone mineral content (BMC), bone mineral density (BMD), and area (A) of the total skeleton, femur, spine, and whole tibia, as well as proximal, middle, and distal areas of the tibia were assessed by dual X-ray absorptiometry (DXA) in an ultra-high-resolution mode. T4 treatment of the SHAM rats did not induce significant changes in BGP level or Pyr/creat excretion compared with the SHAM+Vh control group. However, these two biochemical bone markers significantly increased due to T4 treatment in OVX rats compared with both OVX+Vh and SHAM+T4 groups (P < 0.05 and P < 0.001, respectively). The OVX+T4 group had a significantly lower ΔBMD than SHAM+T4 rats in all studied regions (P < 0.05) except for the middle tibia region. OVX+T4 groups presented a significantly lower ΔBMC and ΔA compared with SHAM+T4 animals (P < 0.001). OVX+T4 rats significantly impaired the ΔBMD in the femur (P < 0.01), spine (P < 0.05), whole (P < 0.05) and middle (P < 0.05) tibia whereas T4 treatment of SHAM rats only affected, significantly, the whole (P < 0.05) and the proximal tibia region (P < 0.01). T4 treatment affects bone growth in young adult rats. The effect is significantly greater in the estrogen-depleted than in the estrogen-repleted state. The bone site most adversely affected by T4 treatment depends on the estrogen status. The proximal tibia (principally trabecular bone) was the most affected area in estrogen-repleted rats. Conversely, in OVX rats, the middle tibia (principally cortical bone) presented the greatest decrease in bone density. Received: 20 May 1999 / Accepted: 4 February 2000     

甲状腺腺瘤和腺瘤性甲状腺肿腺叶切除后甲状腺素的补充

目的：探讨甲状腺腺瘤和腺癌性甲状腺肿一侧甲状腺腺叶切除术后补充甲状腺素的临床意义。方法；将接受一侧甲状腺腺叶切除术的40例甲状腺腺瘤或腺癌性甲状腺肿患者随机分为两组：A组术后口眼甲状腺片，B组术后不服甲状腺片，比较术前及术后3～6个月血清TT3、TT4及TSH值和超声波检查保留侧甲状腺大小。结果：A组手术前后TT3、TT4、TSH值及保留侧甲状腺大小无明显变化，B组术后3～6个月TT3、TT4较术前下降，TSH较术前上升，保留侧甲状腺较术前增大。术后的各项数据两组比较，均有显著性差异。结论：甲状腺腺瘤和腺癌性甲状腺肿一侧腺叶切除术后保留侧甲状腺腺叶有增生，而术后补充甲状腺素可改变这一现象从而预防甲状腺癌的发生。     

先天性甲状腺功能减低的新生儿筛查

目的 总结对新生儿先天性甲状腺功能低下症的筛查和诊治经验，了解扬州地区先天性甲状腺功能低下症的发病率。方法 对出生72h的新生儿采集足跟末梢血，以时间分辨免疫法测血斑中促甲状腺激素（TSH）。结果 本筛查中心2002年7月-2004年12月扬州地区新生儿筛查结果显示，初筛阳性病例106例，确诊20例，先天性甲低的发病率为0．07％，复检率0．38％，召回率98％。结论 先天性甲状腺功能减低症因其出生时没有或很少有甲低的症状和体征而容易误诊，在新生儿期对其筛查可以减少误诊率，使患儿得到早期诊断和治疗，防止症状的发生和发展，避免发生不可逆智能障碍，随着《母婴保健法》的颁布，新生儿筛查工作正在逐步开展，进行大规模的新生儿筛查是非常有必要的。     

甲状腺素片补充治疗对慢性肾脏疾病患者甲状腺激素水平的影响研究

目的 探讨小剂量甲状腺素补充治疗对慢性肾脏疾病患者的甲状腺激素水平、营养不良及左心功能的影响.方法 湖南省人民医院2013年2月至2015年2月间收治的慢性肾脏疾病患者210例,A组为eGFR＜ 15mL ·(min·1.73m2)-1的患者(n=70),B组为15＜ eGFR＜30mL·(min·1.73m2)-1的患者(n=70),C组为30 ＜eGFR ＜60mL·(min·1.73m2)-1的未透析患者(n=70).选择同期本院体检的正常人群为正常对照组(D组,n =70).收集4组患者血液、生化临床资料,检测游离三碘甲状腺原氨酸(free triiodothyronine,FT3)、游离甲状腺素(freethyroxine,FT4)、促甲状腺激素(thyroid stimulating hormone,TSH)、C反应蛋白(C reactive protein,CRP)、左心室射血分数(left ventricular ejection fraction,LVEF)及左心室质量指数(Left ventricular mass index,LVMI),并计算主观综合性营养评估法(subjective global assessment of nutritional act,SGA)等指标.每组根据甲状腺激素水平分为正常组Ⅰ、异常组Ⅱ,观察各组间各指标差异,再给予异常组小剂量甲状腺激素干预后观察各项指标改变.结果 A、B、C组FT3均显著低于D组(P＜0.05),低T3综合征的发生率随eGFR下降而升高;正常组Ⅰ与异常组Ⅱ相比,ALB、CRP、SGA、LVEF、LVMI比较有显著差异(P＜0.05);异常组的FT3与eGFR、SGA、ALB、LVEF呈显著正相关(r=0.912,P＜0.001;r =0.721,P＜0.001;r =0.810,P＜0.001;r=0.903,P＜0.001);FT3与CRP、LVMI呈负相关(r=-0.981,P＜0.001;r=-0.442,P＜0.001);异常亚组给予小剂量甲状腺素治疗后FT3及LVEF较治疗前明显改善(P＜0.05),治疗后eGFR水平只有C2组患者有提高(P＜0.05).结论 甲状腺素水平下降与肾功能严重程度相关,以血清FT3水平降低为主;低水平FT3与营养、左心功能有显著相关性;予以小剂量的甲状腺激素治疗后的低T3及亚临床甲减者的左心收缩功能有提高,中度肾功能损伤的患者eGFR有提高.     

Chronic thyroxine treatment activates the 5-HT2A serotonin receptor in the mouse brain

Chronic thyroxine administration (2.0 mg/l, 60 days) significantly increases the 5-HT2A serotonin receptor gene mRNA level in the frontal cortex and augments the frequency of head twitches induced by the receptor agonist DOI (1.0 mg/kg, i.p.) in AKR mice. The result indicates thyroid hormones involvement in 5-HT2A receptor regulation in adult brain.     

肝硬化严重程度与甲状腺素水平、肝纤维化指标及血清糖链抗原125相关性分析

目的 探讨肝硬化患者Child-Pugh分级与甲状腺素水平、肝纤维化指标以及血清糖链抗原（CA） 125的相关性.方法 选择2010年12月～2012年12月我科就诊的肝硬化患者92例,根据Child-Pugh评分分级分为A级组、B级组和C级组3组,并另设健康对照组.比较各组患者血清甲状腺素水平、肝纤维化指标、血清CA125.结果 3组患者血清总甲状腺素（TT4）、总三碘甲状腺原氨酸（TT3）、游离三碘甲状腺原氨酸（FT3）和游离甲状腺素（FT4）水平均低于对照组,B级组低于A级组,C级组低于B级组（P＜0.05）;3组患者透明质酸（HA）、Ⅳ型胶原（Ⅳ-C）、层黏连蛋白（LN）、Ⅲ型前胶原（PC-Ⅲ）水平均明显高于对照组,B级组高于A级组,C级组高于B级组（P＜0.05）;3组患者分别与对照组比较差异有统计学意义（P＜0.05）;B级组与A级组比较、C级组与B级组比较差异有统计学意义（P＜0.05）.结论 甲状腺素、纤维化指标及CA125可作为肝硬化严重程度Child-Pugh分级法的辅助指标,对准确评估病情和预后具有重要的临床意义.